Acesso livre
Acesso livre

Hematologia Geral

Diretriz NCCN | Doença tromboembólica venosa associada a câncer.

21 Out, 2021 | 11:25h

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Conteúdos relacionados:

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

Systematic Review: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness?

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy


Resumo de Política da OMS | A necessidade urgente de se implementar o manejo de sangue do paciente.

20 Out, 2021 | 11:58h

The urgent need to implement patient blood management: policy brief – World Health Organization


Diretriz | Manejo de agentes anticoagulantes e antiplaquetários na cirurgia cutânea.

19 Out, 2021 | 12:46h

S3 guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery – Journal of the German Society of Dermatology


Mais um estudo observacional sugere que rivaroxabam está associado com taxas mais altas de sangramento gastrintestinal do que outros anticoagulantes orais diretos (DOACs).

19 Out, 2021 | 12:44h

Rivaroxaban Is Associated with Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

Comentário: Rivaroxaban Again Linked to More Bleeding vs Other DOACs – TCTMD

Conteúdo relacionado: Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study – Gastroenterology

 

Comentário no Twitter

 


Estudo randomizado embasa o uso de heparina em dose terapêutica para pacientes não críticos internados por Covid-19.

18 Out, 2021 | 08:57h

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial – The BMJ

Comentário: High-dose of readily available blood thinner reduces risk of death for moderately ill COVID-19 patients – St. Michael’s Hospital

Estudos relacionados (alguns resultados conflitantes)

RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Comentário no Twitter

 


Diretrizes para anestesiologistas sobre o manejo do sangue do paciente em cirurgia cardíaca.

18 Out, 2021 | 08:46h

2021 Clinical Practice Guidelines for Anesthesiologists on Patient Blood Management in Cardiac Surgery – Journal of Cardiothoracic and Vascular Anesthesia

 

Comentário no Twitter

 


Diretrizes ASH 2021 para transplante de célula-tronco em pacientes com doença falciforme.

14 Out, 2021 | 10:43h

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation – Blood

Comunicado de imprensa: ASH Releases New Clinical Practice Guidelines on Stem Cell Transplantation in Sickle Cell Disease

Comentário: ASH Issues Guideline on the Use of HSCT for Sickle Cell Disease – HealthDay


Revisão sistemática | Anticoagulantes orais diretos (DOACs) podem ser benéficos para pessoas em tratamento de câncer que não têm indicação terapêutica ou profilática de anticoagulação.

14 Out, 2021 | 10:35h

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation – Cochrane Library


Prevalência de anemia em mulheres em idade reprodutiva nos países de baixa e média rendas entre 2000 e 2018.

13 Out, 2021 | 13:13h

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018 – Nature Medicine

Comentário convidado: Anemia in women — an intractable problem that requires innovative solutions – Nature Medicine


Estudo randomizado | Não há benefício da terapia antitrombótica (aspirina ou apixabam) para pacientes ambulatoriais com COVID-19 sintomática clinicamente estáveis.

13 Out, 2021 | 12:56h

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial – JAMA

Editorial: Antithrombotic Therapy for Outpatients With COVID-19: Implications for Clinical Practice and Future Research – JAMA

 

Comentário no Twitter

 


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.